Navigation Links
Development of a therapeutic algorithm for optimal nosebleed management
Date:8/26/2013

Approximately 60 percent of people experience epistaxis, commonly known as nosebleed, at least once in their lifetime. Of those who experience nosebleed, six percent require medical treatment. A study in the September 2013 issue of OtolaryngologyHead and Neck Surgery, explores which nosebleed treatment options demonstrate the best outcomes.

"Although data exist on the efficacy of the different epistaxis management techniques, outcome comparisons between the modalities for both primary management as well as management of cases of recurrence are currently lacking," the authors stated.

The study analyzed various treatment outcomes of adult patients with epistaxis presenting to otolaryngologists at a tertiary care center between 2005 and 2011. The authors observed 147 patients (94 men and 53 women) who underwent cauterization, tamponade or nondissolvable packing, and/or proximal vascular control through embolization or surgical ligation. Treatment outcomes were then compared with the intent to derive an algorithm for optimal nosebleed management.

According to the study, nondissolvable packing demonstrated the highest rate of failure or recurrence (57.4 percent) for initial bleed management. Chemical cautery was significantly more successful in achieving lasting hemostasis for the first bleeding episode. The authors also found that the duration of the nondissolvable pack placement had no significant impact on nosebleed recurrence. Furthermore, among patients who failed initial management, those who next underwent more invasive procedures such as cautery, embolization or surgical ligation experienced better outcomes and shorter inpatient stays.

Because the subgroup analyses were limited in size for some of the treatment groups in this study, the authors urge caution when considering these findings.

Although most cases of nosebleed do not require medical intervention, those patients who do present to a tertiary care otolaryngologist and need medical attention require a systematic, stepwise approach to address their condition. This study demonstrates "good outcomes with initial treatment with chemical cautery and with procedures that achieve directed vascular control in patients who develop epistaxis recurrence."


'/>"/>

Contact: Lindsey Walter
newsroom@entnet.org
703-535-3762
American Academy of Otolaryngology - Head and Neck Surgery
Source:Eurekalert

Related medicine news :

1. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
2. Kudos for 3 NJIT Enterprise Development Center high-tech companies
3. 2 repressor genes identified as essential for placental development
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Advanced genetic screening method may speed vaccine development
6. New biospecimens management system in development
7. Developmental Woes Common in Siblings of Children With Autism
8. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
9. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
10. Study sheds new light on role of genetic mutations in colon cancer development
11. The first day of development -- a window to successful pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 18, 2017 , ... ... the latest information and contact points to easily connect elderly veterans of America's ... living, and elder-care funding. It also conveys material on this year's increase in ...
(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... ... 17, 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, ... and non-controlled substances plus the ability to manage orders on their desktop or ... accept electronic prescriptions, according to the Office of the National Coordinator of Health ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... be asking before selecting an FDA approval pathway? , How should they ...
(Date:2/17/2017)... ... 17, 2017 , ... Corrective Action & Preventive Action for ... Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/capamd      ... action (PA)? , The methods share techniques and tools but they are different ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology: